Vipergen is a world leading provider of small molecule drug discovery services based on DNA-encoded library (DEL) technologies. Vipergen is finding tractable hits/leads for your pharmaceutical relevant targets, using three proprietary 2nd and 3rd generation DEL technologies. Vipergen is offering different business models, including simple Fee-For-Service. Recent News - Copenhagen, Denmark, November 6th, 2020 - Commercial release of the first technology for DEL screening inside a living cell - Vipergen ApS announced today the commercial release of the first technology for screening of DNA-encoded small molecule libraries (DELs) inside a living cell. This proprietary technology will significantly accelerate and improve the drug discovery process. YoctoReactor® – Technology platform for synthesizing DNA-encoded chemical libraries • 100% match between the DNA-code and the synthesized small molecule is ensured by purification steps after each chemical reaction (unique capability) and use of robust chemistries Binder Trap Enrichment® – Technology platform for DEL screening in a homogeneous assay • As a homogeneous assay, BTE delivers high fidelity and a low false positive rate by avoiding surface artifacts and the complexity of matrix binding • Instant specificity – multiplexed screening of target and anti-targets (unique capability) Cellular Binder Trap Enrichment® – Technology platform for DEL screening in a living cell • As an in vivo assay, cBTE delivers lower attrition rate (unique capability) • No need for purified active target protein – cBTE accommodates a broader target space (unique capability)